LeukemiaASCO23
The three-year cumulative incidence of relapse was 4% in those receiving cladribine and low-dose cytarabine plus venetoclax.
Of the 8,081 patients evaluated, 4,808 received treatment within 24 months of a novel therapy approval.
The real-world analysis of racial disparities in CLL accounted for the treatment that patients received.
Advertisement
Dr. Cortes and colleagues presented the research during the 2023 American Society of Clinical Oncology Annual Meeting.
The study included patients who received at least two prior lines of therapy, including a BTK inhibitor.
Older adult patients with newly diagnosed Ph- ALL may benefit from this combination therapy.
Advertisement
In this poor-risk population of patients, 73% responded to the triplet.
Researchers reported real-world patterns and outcomes by race and line of therapy in a poster presentation at ASCO.
However, more than half (53%) of patients discontinued at least one venetoclax regimen.
Dr. Hill and colleagues presented their research on the CAR-T manufacturing approach during the 2023 ASCO meeting.
The study is currently enrolling patients who have previously received a Bruton tyrosine kinase inhibitor.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.